KAS
NPCE icon

Kemnay Advisory Services’s Neuropace NPCE Stock Holding History

Kemnay Advisory Services’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-4,522
Closed -$59.5K – 1293
2026
Q1 		$59.5K Buy
4,522
+3,869
+592% +$58K 0.01% 223
2025
Q4 		$10.1K Buy
+653
New +$8.73K ﹤0.01% 747

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Kemnay Advisory Services's NPCE Position: Q2 2026 in Review

Kemnay Advisory Services sold out of Neuropace (NPCE) in Q2 2026, closing a stake of 4,522 shares — an estimated $59.5K sold.

Kemnay Advisory Services first reported a position in NPCE in Q4 2025 and held it in 2 quarters. The position peaked at $59.5K in Q1 2026. 113 funds tracked by Wall St. Rank hold NPCE as of Q2 2026.

  • Kemnay Advisory Services reported no remaining Neuropace position as of Q2 2026 after selling out during the quarter.
  • Kemnay Advisory Services sold 4,522 Neuropace shares in Q2 2026, an estimated $59.5K.
  • Kemnay Advisory Services first reported a position in Neuropace in Q4 2025 and held it in 2 quarters.
  • Kemnay Advisory Services's Neuropace position peaked at $59.5K in Q1 2026.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q2 2026.

Based on Kemnay Advisory Services's 13F filing for Q2 2026, filed 14 Aug 2026.